Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®
Phase III, multicenter, randomized, double-blinded, prospective study with two parallel treatment groups. Patients who present to the hematologist/oncologist and satisfy all inclusion and exclusion criteria will be eligible for participation in this 18-week study.
Cancer and Chemotherapy Related Anemia
DRUG: Injectafer|OTHER: Normal Saline
Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Week 3 to Week 18, The following participants will be considered to have met the primary endpoint:

* Participants with observed Hgb decrease from baseline between 0.5 g/dL to 1.0 g/dL on two consecutive visits between Weeks 3 and 18.
* Participants with observed Hgb decrease from baseline ≥1.0 g/dL at one visit.
* Participants who have a non-study intervention prior to Week 18.
* Participants who discontinue prior to Week 18 for lack of efficacy or adverse events., Week 3 to Week 18
Change in Hemoglobin From Baseline to Week 18 or to Nonstudy Intervention, Nonstudy Intervention is defined as any of the following:

* Initiation of erythropoietin for any reason
* Blood transfusion
* IV iron
* Prescribed use of oral iron, Baseline to Week 18|Percentage of Participants With Hemoglobin Increase From Baseline ≥ 1 g/dL at Any Postbaseline Visits Without Receiving a Nonstudy Intervention, Summary of number and percentage(%) of participants with Hgb increase ≥ 1 g/dL increase at any time point in the absence of non-study intervention., Baseline to Week 18|Percentage of Participants Who Received Nonstudy Intervention, Intervention is defined as any of the following:

* Initiation of erythropoietin for any reason
* Blood transfusion
* IV iron
* Prescribed use of oral iron, Baseline to week 18|Percentage of Participants With Hemoglobin > 12 g/dL in the Absence of Non-study Intervention, Intervention is defined as any of the following:

* Initiation of erythropoietin for any reason
* Blood transfusion
* IV iron
* Prescribed use of oral iron, Baseline to week 18|Time to Hemoglobin Increase ≥ 1 g/dL in the Absence of Non-study Intervention, Participants who discontinued or completed the study, or received a non-study intervention before having an increased in Hgb ≥ 1 g/dL will be censored at last study visit or time of receiving non-study intervention, respectively, Baseline to Week 18|Percentage of Participants Requiring a Blood Transfusion, Summary of the number (percentage) of participants requiring a blood transfusion at any time during the trial., Baseline to week 18|Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit, Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit., Baseline to Day 7|Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit, Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit., Baseline to Week 2|Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit, Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit., Baseline to Week 3|Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit, Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit., Baseline to Week 6|Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit, Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit., Baseline to Week 9|Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit., Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit., Baseline to Week 12|Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit., Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit., Baseline to Week 15|Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit, Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit., Baseline to Week 18|Time to a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Week 18, Patients who discontinued or completed the study, or received a nonstudy intervention before having an increase in Hgb ≥ 0.5 g/dL were censored at last study visit or time of receiving nonstudy intervention, respectively., Baseline to Week 18|Time to a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Week 18, Patients who discontinued or completed the study, or received a nonstudy intervention before having an increase in Hgb ≥ 0.5 g/dL were censored at last study visit or time of receiving nonstudy intervention, respectively., From Baseline to Week 18|Correlation of Change in Hemoglobin With Baseline Hepcidin Level, For participants who receive non-study intervention or early withdraw from the study, the time of intervention or early withdrawal will be considered as end of study, respectively., Baseline to Week 18.|Total Score of the Functional Assessment of Chronic Illness Therapy Fatigue(FACIT-Fatigue) Scale Mean Change From Baseline to Week 18, Summary of the actual value and change from baseline in total score of Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue Scale). Ranges from 0-52 and higher scores mean better Quality of Life (QOL). Data collected after receiving non-study intervention will not be included in the summary., Baseline to Week 18
This is a Phase III, multicenter, randomized, double-blinded, prospective study with two parallel treatment groups. Patients who present to the hematologist/oncologist and satisfy all inclusion and exclusion criteria will be eligible for participation in this 18-week study. Subjects who meet all inclusion criteria and no exclusion criteria, will be randomized into the trial (Group A or B).